Common immune-related toxicity related to toripalimab in its combination with axitinib included diarrhea (60.6%), hypothyroidism (51.5%), alanine aminotransferase increased (42.4%), rash (36.4%), and aspartate aminotransferase increased (33.3%) (Sheng et al. 2019). This evidence concerns the gene GPT and hypothyroidism.